Evidence map›Paper›PMID 27728802›Full record

ArticleCancer cell2016

Targeting HIF2α in Clear-Cell Renal Cell Carcinoma.

Christopher J Ricketts, Daniel R Crooks, W Marston Linehan

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. HIF in Gastric Cancer: Regulation and Therapeutic Target.Molecules (Basel, Switzerland) · 2022
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Genetic and metabolic hallmarks of clear cell renal cell carcinoma.Biochimica et biophysica acta. Reviews on cancer · 2018
    Review
  18. Article
  19. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Christopher J RickettsUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1107, USA.
Daniel R CrooksUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1107, USA.
W Marston LinehanUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1107, USA. Electronic address: wml@nih.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In two recent studies, the HIF2α antagonist, PT2399, decreased HIF2α-dependent transcription and tumor growth in selected VHL-deficient clear-cell renal cell carcinoma (ccRCC) models. These studies validate HIF2α as a therapeutic target in ccRCC, reveal variable sensitivity to HIF2α antagonism, and provide the foundation for predictive biomarker-driven clinical trials.

Indexed as

AnimalsBasic Helix-Loop-Helix ProteinsCarcinoma, Renal CellEndothelial PAS Domain-Containing Protein 1HumansIndansKidney NeoplasmsMiceMice, NudeMolecular Targeted TherapySulfonesBasic Helix-Loop-Helix ProteinsEndothelial PAS Domain-Containing Protein 1IndansPT2399Sulfones

Identifiers

PMID27728802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.